stockrowCytokinetics, Incorporated
CYTK Healthcare Biotechnology
Cytokinetics, Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $88.0 million, up 376.6% from fiscal 2024.
- Revenue
- +2,356.5%
- EPS
- +46.3%
- Free cash flow
- −6.73%
- Total debt
- −83.9%
Quarter to September 2026, against a year earlier
Follow CYTK
Alert me
Cytokinetics, Incorporated (CYTK) EBITDA
Cytokinetics, Incorporated's EBITDA for fiscal 2025 was −$602.1M, compared with −$526.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was −$694.7M. Over the past ten years it has ranged from −$602.1M (fiscal 2025) to $19.4M (fiscal 2016) — the current reading is the lowest in ten years. EBITDA has fallen for 5 consecutive fiscal years. Cytokinetics, Incorporated ranks 587th of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | −$602.1M | — |
| FY2024 | −$526.7M | — |
| FY2023 | −$484.3M | — |
| FY2022 | −$318.4M | — |
| FY2021 | −$184.0M | — |
| FY2020 | −$92.1M | — |
| FY2019 | −$97.6M | — |
| FY2018 | −$87.7M | — |
| FY2017 | −$111.5M | — |
| FY2016 | $19.4M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | −$163.4M | — |
| Jun 2026 | −$175.5M | — |
| Mar 2026 | −$180.2M | — |
| Dec 2025 | −$175.5M | — |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| KRYS Krystal Biotech, Inc. compare | $234.3M |
| CAI Caris Life Sciences,�Inc. compare | $180.0M |
| CORT Corcept Therapeutics Incorporated compare | $108.8M |
| PTGX Protagonist Therapeutics, Inc. compare | $56.4M |
| TWST Twist Bioscience Corporation compare | −$119.6M |
| MDGL Madrigal Pharmaceuticals, Inc. compare | −$145.8M |
| ARWR Arrowhead Pharmaceuticals, Inc. compare | −$204.6M |
| SYRE Spyre Therapeutics, Inc. compare | −$250.2M |
| CYTK Cytokinetics, Incorporated | −$694.7M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on CYTK
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement